Eusol Biotech Co.,Ltd. (TPEX:6652)

Eusol Biotech Statistics

Total Valuation

Eusol Biotech has a market cap or net worth of TWD 268.52 million. The enterprise value is -21.03 million.

Market Cap	268.52M
Enterprise Value	-21.03M

Important Dates

The next estimated earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Eusol Biotech has 137.00 million shares outstanding.

Current Share Class	137.00M
Shares Outstanding	137.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	47.95%
Owned by Institutions (%)	2.06%
Float	67.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	129.28
PB Ratio	0.81
P/TBV Ratio	0.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.52
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.60

Financial Position

The company has a current ratio of 31.59, with a Debt / Equity ratio of 0.03.

Current Ratio	31.59
Quick Ratio	31.26
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.32
Interest Coverage	-359.50

Financial Efficiency

Return on equity (ROE) is -11.54% and return on invested capital (ROIC) is -116.38%.

Return on Equity (ROE)	-11.54%
Return on Assets (ROA)	-8.09%
Return on Invested Capital (ROIC)	-116.38%
Return on Capital Employed (ROCE)	-13.89%
Weighted Average Cost of Capital (WACC)	3.72%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	39
Asset Turnover	0.01
Inventory Turnover	0.69

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.55% in the last 52 weeks. The beta is -0.08, so Eusol Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.08
52-Week Price Change	-67.55%
50-Day Moving Average	5.80
200-Day Moving Average	6.37
Relative Strength Index (RSI)	21.53
Average Volume (20 Days)	1,149,797

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Eusol Biotech had revenue of TWD 2.08 million and -40.42 million in losses. Loss per share was -0.30.

Revenue	2.08M
Gross Profit	668,000
Operating Income	-47.10M
Pretax Income	-40.42M
Net Income	-40.42M
EBITDA	-46.28M
EBIT	-47.10M
Loss Per Share	-0.30

Balance Sheet

The company has 300.82 million in cash and 11.27 million in debt, with a net cash position of 289.55 million or 2.11 per share.

Cash & Cash Equivalents	300.82M
Total Debt	11.27M
Net Cash	289.55M
Net Cash Per Share	2.11
Equity (Book Value)	330.02M
Book Value Per Share	2.41
Working Capital	317.80M

Cash Flow

In the last 12 months, operating cash flow was -32.54 million and capital expenditures -2.45 million, giving a free cash flow of -34.98 million.

Operating Cash Flow	-32.54M
Capital Expenditures	-2.45M
Depreciation & Amortization	812,000
Net Borrowing	-2.36M
Free Cash Flow	-34.98M
FCF Per Share	-0.26

Margins

Gross Margin	32.16%
Operating Margin	-2,267.45%
Pretax Margin	-1,945.88%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Eusol Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-15.05%
FCF Yield	-13.03%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Eusol Biotech has an Altman Z-Score of 23.21 and a Piotroski F-Score of 2.

Altman Z-Score	23.21
Piotroski F-Score	2